Publications by authors named "Aisa Fornovi"
Article Synopsis
- Monoclonal antibodies targeting PCSK9 significantly lower LDL cholesterol levels by about 55% in patients, but their impact on other lipid parameters like cholesterol remnants is less clear.
- A study analyzing data from 652 patients across 14 hospitals in Spain showed that treatment with PCSK9 inhibitors not only reduced LDL cholesterol but also led to significant decreases in other lipid measures, including the triglycerides-to-HDL ratio and cholesterol remnants.
- The findings indicate that over one-third of patients achieved LDL cholesterol below 55 mg/dl and lower cholesterol remnants, suggesting that PCSK9 inhibitors are effective in managing lipid residual risk as well as LDL cholesterol levels.
Background: Previous evidence supports that monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDLc) by 50%-65%, regardless of baseline treatments. We tested possible sex differences in a multicentre registry of real-world patients treated with PCSK9 inhibitors.
Methods: This is a multicentre and retrospective study of 652 patients initiating treatment with any PCSK9 inhibitor in 18 different hospitals.
Introduction And Objectives: Bariatric surgery is a valuable tool for metabolic control in obese diabetic patients. The aim of this study was to determine changes in weight and carbohydrate and lipid metabolism in obese diabetic patients during the first 4 years after bariatric surgery.
Methods: A retrospective study was performed in 104 patients (71 women; mean age, 53.